Image
Clinical Research Updates™

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

Clinician Resource

PCSK9 Inhibitor Clinic Model

Educational materials for clinicians.

Patient Resources

Centers for Disease Control and Prevention

Educational materials for patients with high cholesterol.

American Heart Association

Resources on managing hyperlipidemia by controlling cholesterol and triglycerides.

The FH Foundation

A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).

Clinical Assessment Tools

ASCVD Risk Estimator

Dutch Lipid Clinic Network Score for Familial Hypercholesterolemia

Guidelines

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Grundy SM, et al. Circulation. 2019;139(25):e1046-e1081.

Suggested Readings

PCSK9 inhibitor valuation: a science-based review of the two recent models.

Baum SJ, Cannon CP. Clin Cardiol. 2018;41(4):544-550.

Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease.

Fonarow GC, et al. JAMA Cardiol. 2017;2(10):1069-1078.

Evolocumab for treatment of high cholesterol: effectiveness and value.

Institute for Clinical and Economic Review. 2017.

Alirocumab for treatment of high cholesterol: effectiveness and value.

Institute for Clinical and Economic Review. 2019.

Application of PCSK9 inhibitors in practice: challenges and opportunities.

Kaufman TM, et al. Circ Res. 2017;121(5):499-501.

Application of PCSK9 inhibitors in practice: the patient experience.

Kaufman TM, et al. Circ Res. 2019;124(1):32-37.

Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY Outcomes trial.

Kazi DS, et al. Ann Intern Med. 2019;170(4):221-229.

Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial.

Murphy SA, et al. JAMA Cardiol. 2019;4(7):613-619.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial.

Schwartz GG, et al. Am Heart J. 2014;168(5):682-689.

Alirocumab and cardiovascular outcomes after acute coronary syndrome.

Schwartz GG, et al. N Engl J Med. 2018;379(22):2097-2107.

Evolocumab and clinical outcomes in patients with cardiovascular disease.

Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.

Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial.

Szarek M, et al. J Am Coll Cardiol. 2019;73(4):387-396.

Interactive Presentation

Dr Sergio Fazio discusses his PCSK9 inhibitor clinic model


Activity
Pharmacoeconomics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options